Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the ...

The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates. Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development ...

Stargazers in the U.S. will find the slender form of the crescent moon roughly 20 degrees above the western horizon right at ...

Regulus Therapeutics Inc has a consensus price target of $7.71 based on the ratings of 7 analysts. The high is $11 issued by Canaccord Genuity on April 30, 2025.The low is $3 issued by Wells Fargo ...

DelveInsight's Polycystic Kidney Disease Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Polycystic Kidney Disease treatment.

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

The best time to catch Mars and Regulus — known as the "Heart of the Lion"— will be just after twilight fades and the stars ...

Novartis has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc., marking a significant step ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...